Download presentation
Presentation is loading. Please wait.
Published byDortha Maxwell Modified over 6 years ago
1
Changing the Paradigm of Treatment in Patients With Hodgkin Lymphoma
2
Outline of the Program
3
Statistics
4
Pathology
5
Cellular Interactions in the Microenvironment
6
Clinical Significance of the Tumor Microenvironment
13
Preventing Immune Escape Targeting CD30 With Brentuximab Vedotin
18
How Does Immune Checkpoint Blockade work? Blocking PD-1
26
Nivolumab Durability of Response
27
Nivolumab: Treatment-Related AEs
29
Pembrolizumab Durability of Response
31
PD-L1 Expression
32
Phase 2 Data With PD-1 Blockade: Nivolumab
33
Phase 2 Data With PD-1 Blockade: Pembrolizumab
35
ECHELON-1: ABVD vs AVD+BV as Frontline Therapy in Stage III/IV HL
36
Combination Approaches Brentuximab Vedotin + Ipilimumab
37
Conclusions
38
Abbreviations
39
Abbreviations (cont)
40
Abbreviations (cont)
41
Abbreviations (cont)
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.